BIOHARVEST SCIENCES INC. (BHST) Form 6-K — Oct 13, 2026
BioHarvest Sciences announced that its proprietary Olive Cell composition has reached commercial readiness, completing plant-cell development, large-scale bioreactor scale-up, commercial manufacturing validation and the self-affirmed GRAS process. The asset, standardized for high concentrations of the polyphenol Verbascoside, is now available for licensing and production through the company's CDMO business at its GMP facility. It is BioHarvest's second plant-cell-derived composition to reach this stage after VINIA.
Key figures
- Steatosis lipid reduction
- up to 37%
- Fibrosis collagen reduction
- up to 50%
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.